2 news items
Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs; Says 201 Trial Is ~75% Enrolled
IKT
18 Apr 24
, we expect to request an end of Phase 2 meeting with the FDA by the end of 2024, which further accelerates our goal to begin enrolling the extension
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
IKT
18 Apr 24
meeting with the FDA by the end of 2024, which further accelerates our goal to begin enrolling the extension study as soon as possible
- Prev
- 1
- Next